Juvenile Dermatomyositis
21
6
6
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
14%
3 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (21)
Environmental Risk Factors for the Anti-synthetase Syndrome
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Comparison Of The Effects Of Two Different Exercise Training Based On Internal And External Focus In Children and Adolescents With Rheumatic Diseases
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Fitness Integrative Training for Pediatric Rheumatology Disorders
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
Clinical Analysis of Juvenile Dermatomyositis Patients
Yellow Fever Vaccine in Patients With Rheumatic Diseases
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis
Juvenile Dermatomyositis
Incidence and Prevalence of Juvenile Dermatomyositis
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
The CARRA Registry
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)